Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. develops and markets orthopaedic medical devices for the surgical treatment of bunions and related midfoot deformities. Its updates center on the Lapiplasty® 3D Bunion Correction procedure and related technologies used by surgeons, ambulatory surgery centers and hospitals.
Recurring news themes for TMCI include quarterly and annual financial results, revenue guidance, surgeon adoption, cash and liquidity updates, product introductions and clinical data. Company announcements also cover additions to the bunion and midfoot technology portfolio, including SuperBite™ Compression Screw System, Lapiplasty® Lightning™ technology, SpeedMTP® and IntelliGuide® PSI, as well as patent portfolio activity and presentations at foot and ankle surgery conferences.
Treace Medical Concepts (Nasdaq: TMCI) announced an upsized initial public offering (IPO) of 11,250,000 shares, priced at $17.00 each, aiming to raise approximately $106.3 million before expenses. Of these, 6,250,000 shares are offered by Treace while 5,000,000 shares are from selling stockholders. The offering includes a 30-day option for underwriters to purchase an additional 1,687,500 shares. Trading on the Nasdaq is set to start on April 23, 2021, with the closing anticipated on April 27, 2021, pending customary conditions.